Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Colorectal Neoplasms 3Colonic Neoplasms 3Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Leukemia 1Kidney Neoplasms 1Breast Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 23Paclitaxel 18Bevacizumab 16Radiotherapy 15Erlotinib Hydrochloride 13Cisplatin 9Gemcitabine 7Gefitinib 7Docetaxel 7Taxes 6Pemetrexed 6Cetuximab 4Etoposide 3Amplified Fragment Length Polymorphism Analysis 3pegfilgrastim 2Vinorelbine 2Topotecan 2Radiotherapy, Conformal 2Radiation 2Irinotecan 2Gene Expression Profiling 2Anterior Temporal Lobectomy 2vandetanib 1sargramostim 1romidepsin 1lentiviral minigene vaccine of COVID-19 coronavirus 1irofulven 1cositecan 1advexin 1Video-Assisted Surgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma, Bronchiolo-Alveolar × Chromosome Mapping × Clear all
NCT00897533 2017-05-19

Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer

Eastern Cooperative Oncology Group

Completed
137 enrolled
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡